May 11, 2020 / 9:34 PM / 25 days ago

BRIEF-Novavax to Receive up to $388 Mln Funding from CEPI for COVID-19 Vaccine Development and Manufacturing

May 11 (Reuters) - Novavax:

* NOVAVAX TO RECEIVE UP TO $388 MILLION FUNDING FROM CEPI FOR COVID-19 VACCINE DEVELOPMENT AND MANUFACTURING

* CEPI FUNDING WILL ALLOW CO TO INCREASE ITS LARGE-SCALE MANUFACTURING CAPACITY FOR ANTIGEN AND ADJUVANT IN MULTIPLE LOCATIONS

* ADDITIONAL FUNDING FROM CEPI WILL ALSO SUPPORT RAPID SCALE-UP OF NVX-COV2373 VACCINE ANTIGEN, CO’S PROPRIETARY MATRIX-M ADJUVANT

* PLANS TO USE CEPI FUNDING TO ADVANCE NVX-COV2373 WITH A PHASE 1/2 CLINICAL TRIAL WITH PHASE I PORTION STARTING IN AUSTRALIA THIS MAY Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below